Please login first

The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response

01/02/2021 - 14/02/2021

DNA Damage Response (DDR), DNA Repair, Cell Cycle Checkpoints, Synthetic Lethality, DDR Targeted Therapy: Preclinical and Clinical Studies, Immune Checkpoints, Biomarkers
Add this event to bookmarks
Contact Us

Announcement

Warmest congratulations on the success of the 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response (IECC2021). Many thanks for your participation.
All participants of IECC2021 are welcome to submit the extended work to the Cancers (IF 6.126) Special Issue “IECC2021: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response”.

Welcome from the Chairs

Dear Colleagues,

We are pleased to announce the 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response: 114 February 2021

Defects in the DNA damage response (DDR), comprising DNA repair and cell cycle checkpoint signalling, can promote tumorigenesis by creating increased genomic instability. These defects create tumour vulnerabilities that can be exploited for therapeutic gain. This conference aims to promote and advance the exciting and rapidly changing field of exploiting DDR dysregulation for cancer therapy. It will bring together experts in basic, translational and clinical research to discuss the current research and the opportunities and obstacles that lie ahead of the field, as we seek to translate the concepts of synthetic lethality, gene addiction and checkpoint inhibition into cancer therapies together.

The focus of this conference is the translation of basic science understanding of the DNA damage response (DDR), and its dysregulation in cancer to its therapeutic exploitation. Topics of interest include, but are not limited to:

  • DNA function and its dysregulation in cancer, including epigenetic and post-translational mechanisms
  • Role of the DDR in immune signalling
  • Targeted therapies exploiting DDR dysregulation and translation of determinants of sensitivity to predictive biomarkers
  • Clinical studies with DDR-targeted therapies

There will be seven specific sessions:

  • Session 1: Overview of targeting DDR dysfunction in cancer
  • session 2: DNA damage cell cycle checkpoints
  • Session 3: DNA repair, defects in cancer and their exploitation
  • Session 4: MMR defects, mutator phenotype
  • Session 5: SUMO and ubiquitination and other epigenetic and post-translational mechanisms
  • Session 6: Targeting with immune checkpoint inhibitors
  • Session 7: Overview and use of biomarkers in clinical trials

and a poster session. Posters can be presented without an accompanying proceedings paper, and will be available online on this website, during and after the e-conference. However, they will not be added to the proceedings of the conference.

Participants will have the opportunity to examine, explore and critically engage with issues and advances in these areas. We hope to facilitate discussions and exchange within the community.

This event will solely be an online proceeding which allows participation from all over the world, with no concerns for travel and related expenditures. This type of conference is particularly appropriate and useful because research concerned with cancers is progressing rapidly. An electronic conference provides a platform for rapid and direct exchanges about the latest research findings and novel ideas. Participation, as well as the “attendance” of this online conference, is free of charge.

The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response will be held at IECC2021.sciforum.net, on a platform developed by MDPI to organize electronic conferences.

The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response is sponsored by MDPI and the scientific journal Cancers. Accepted conference papers will be published in the proceedings of this e-conference. All participants are cordially invited to contribute with a extended full manuscript to Cancers Special Issue IECC2021: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response with a 20% discount off the APC. Cancers (ISSN 2072-6694; IF 6.126) is a peer-review Open Access journal of oncology published semimonthly online by MDPI.

The best conference paper and presentation will receive an award of 500 CHF, as well as an offer to publish an extended paper, free of charge, in the Special Issue of the journal Cancers.

We hope the community will share this enthusiasm and help making this conference a success.

Kind regards,
Prof. Dr. Nicola Curtin
Dr. Helen E. Bryant


Conference Secretariat

Ms. Dimity Wang
Ms. Donna Xue
[email protected]

Time Schedule

Abstract Deadline: 6 December 2020
Abstract Acceptance Notification Deadline: 20 December 2020
Full Paper Submission Deadline: 20 January 2021
Conference Date: 1–14 February 2021
Live Sessions: 1–3 February 2021
Awards Announcement: 30 April 2021


Conference Chairs

Prof. Dr. Nicola Curtin

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK

Dr. Helen E. Bryant

Department of Oncology and Metabolism, The Medical School, Beech Hill Road, Sheffield S10 2RX, UK

Conference Committee

Dr. Susan Lees-Miller

Department of Biochemistry and Molecular Biology, Robson DNA Science Centre, Arnie Charbonneau Cancer Institute, University of Calgary,Calgary, Alberta, Canada

DETAILS

Dr. Lees-Miller received her PhD from the University of Wales in the UK, then had a postdoctoral fellowship at the University of Alberta in Canada and at Brookhaven National Laboratory in NY, USA. In 1992 she returned to Canada to take up a Faculty position at the University of Calgary. From 2003 to 2018 Dr. Lees-Miller held the Engineered Air Chair in Cancer Research and until 2020 was head of the Robson DNA Science Centre at the University of Calgary. Her research focusses on the role of the phosphatidylinositol-3 kinase-like protein kinases DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and Ataxia-Telangiectasia Mutated (ATM) in the DNA damage response. She has published over 180 peer-reviewed articles that have been cited over 20,000 times. In 2011, Dr. Lees-Miller was elected to the Royal Society of Canada in recognition of her work on the DNA damage response.

Bio
Dr. Lees-Miller received her PhD from the University of Wales in the UK, then had a postdoctoral fellowship at the University of Alberta in Canada and at Brookhaven National Laboratory in NY, USA. In 1992 she returned to Canada to take up a Faculty position at the University of Calgary. From 2003 to 2018 Dr. Lees-Miller held the Engineered Air Chair in Cancer Research and until 2020 was head of the Robson DNA Science Centre at the University of Calgary. Her research focusses on the role of the phosphatidylinositol-3 kinase-like protein kinases DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and Ataxia-Telangiectasia Mutated (ATM) in the DNA damage response. She has published over 180 peer-reviewed articles that have been cited over 20,000 times. In 2011, Dr. Lees-Miller was elected to the Royal Society of Canada in recognition of her work on the DNA damage response.

Dr. Sarah-Anne Martin

Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK

DETAILS

Sarah Martin is a Reader in Cancer Cell Biology from Queen Mary University of London, where her research is largely focused on investigating the role of the DNA mismatch repair (MMR) pathway in tumourigenesis and how loss of this pathway can be therapeutically targeted. Her recent focus has been on investigating the role of MMR loss and its influence on mitochondrial metabolism, and how this may impact disease progression and treatment.

Bio
Sarah Martin is a Reader in Cancer Cell Biology from Queen Mary University of London, where her research is largely focused on investigating the role of the DNA mismatch repair (MMR) pathway in tumourigenesis and how loss of this pathway can be therapeutically targeted. Her recent focus has been on investigating the role of MMR loss and its influence on mitochondrial metabolism, and how this may impact disease progression and treatment.

Prof. Dr. Jo Morris

Birmingham Centre for Genome Biology, Institute of Cancer and Genomic Sciences, Medical and Dental Schools, University of Birmingham, Birmingham, UK.

DETAILS

Jo is interested in the Ubiquitin and SUMO and other post-translation systems and how they relate to the regulation of mammalian DNA repair and DNA replication. This includes how the BRCA1 ubiquitin ligase contributes to 53BP1 placement in DNA repair, how deSUMOylation regulates DNA repair timing through MDC1 regulation, and how proline isomerisation regulates replication fork protection through altering RAD51 interactions.

Bio
Jo is interested in the Ubiquitin and SUMO and other post-translation systems and how they relate to the regulation of mammalian DNA repair and DNA replication. This includes how the BRCA1 ubiquitin ligase contributes to 53BP1 placement in DNA repair, how deSUMOylation regulates DNA repair timing through MDC1 regulation, and how proline isomerisation regulates replication fork protection through altering RAD51 interactions.

Dr. Jason Parsons

Department of Molecular and Clinical Cancer Medicine, Cancer Research Centre, University of Liverpool, 200 London Road, Liverpool L3 9TA, UK

Dr. Randi Syljuåsen

Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

Dr. Ruth H. Thompson

Unit of Molecular Oncology, University of Sheffield, Sheffield, UK

Invited Speakers

Prof. Dr. Karlene A. Cimprich

Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA

Invited Talk:
The Causes and Consequences of Replication Stress

Karlene Cimprich is a Professor at Stanford University in the Department of Chemical and Systems Biology. She is particularly interested in how cells maintain genomic stability during DNA replication. Her lab studies replication stress signalling by the checkpoint kinase ATR, which she cloned as a postdoctoral fellow, and DNA damage tolerance pathways, which help to suppress replication stress. Her lab also studies R-loops and the mechanisms by which they cause DNA damage, interfere with replication, and induce genome instability. Dr. Cimprich serves on several Editorial Boards, has organized a number of international meetings, and is a recipient of numerous awards. She is also an AAAS fellow and an American Cancer Society Research Professor.

Dr. Susan Lees-Miller

Department of Biochemistry and Molecular Biology, Robson DNA Science Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada

Invited Talk

Dr. Lees-Miller received her PhD from the University of Wales in the UK, then had a postdoctoral fellowship at the University of Alberta in Canada and at Brookhaven National Laboratory in NY, USA. In 1992 she returned to Canada to take up a Faculty position at the University of Calgary. From 2003 to 2018 Dr. Lees-Miller held the Engineered Air Chair in Cancer Research and until 2020 was head of the Robson DNA Science Centre at the University of Calgary. Her research focusses on the role of the phosphatidylinositol-3 kinase-like protein kinases DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and Ataxia-Telangiectasia Mutated (ATM) in the DNA damage response. She has published over 180 peer-reviewed articles that have been cited over 20,000 times. In 2011, Dr. Lees-Miller was elected to the Royal Society of Canada in recognition of her work on the DNA damage response.

Dr. Sarah-Anne Martin

Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK

Invited Talk

Sarah Martin is a Reader in Cancer Cell Biology from Queen Mary University of London, where her research is largely focused on investigating the role of the DNA mismatch repair (MMR) pathway in tumourigenesis and how loss of this pathway can be therapeutically targeted. Her recent focus has been on investigating the role of MMR loss and its influence on mitochondrial metabolism, and how this may impact disease progression and treatment.

Prof. Dr. Jo Morris

School of Education, Department of STEM Education, Physics

Birmingham Centre for Genome Biology, Institute of Cancer and Genomic Sciences, Medical and Dental Schools, University of Birmingham, Birmingham, UK

Invited Talk

Jo is interested in the Ubiquitin and SUMO and other post-translation systems and how they relate to the regulation of mammalian DNA repair and DNA replication. This includes how the BRCA1 ubiquitin ligase contributes to 53BP1 placement in DNA repair, how deSUMOylation regulates DNA repair timing through MDC1 regulation, and how proline isomerisation regulates replication fork protection through altering RAD51 interactions.

Dr. Juanita Suzanne Lopez

Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK

Invited Talk

Dr Juanita Lopez is a Consultant Medical Oncologist at the Phase I Drug Development Unit at the Royal Marsden and the Institute of Cancer Research, specialising in early phase translational drug development and the treatment of patients with brain tumours. Dr Lopez graduated from the University of Cambridge with a double first class in 2001, obtaining numerous prizes and completing an intercalated laboratory research year in development neurosciences. She then completed her general medical training in London, and was awarded the MRCP in 2004. She was awarded a four year Clinical Research Training Fellowship from Avon-Breakthrough Breast Cancer to carry out laboratory research at the ICR, which led to the award of a PhD. Her main research interests lie in understanding the interplay between inflammation, immune responses and cancer, and rationally developing novel treatments and combinations. She has served as UKCI for a number of early phase clinical trials including first-in-human trials, as well as several for brain tumours.

Dr. Yvette Drew

Northern Institute for Cancer Research, Newcastle University, Newcastle, UK


Invited Talk:
Functional elastomers responsive to electrical and mechanical stress

Dr Yvette Drew is a Clinical Senior Lecturer and Honorary Consultant in Medical Oncology in at the Northern Centre for Cancer Care (NCCC) and the Clinical and Translational Research Institute, Newcastle University. She undertook specialist medical oncology training at the Beatson West of Scotland Cancer Centre, Glasgow and the NCCC. During this time she was awarded a CRUK-funded PhD fellowship investigating the role of PARP inhibitors in homologous-recombination-deficient ovarian cancer. During her PhD she won a Merit award for her research from the American Society of Clinical Oncology (ASCO) and was awarded the Medical Sciences Doctoral Prize (Newcastle University, 2013). She has played a key role in both the pre-clinical and clinical development of PARP inhibitors in ovarian cancer. Her current post is split between the systemic management of gynaecological cancers and the development of novel therapies through early phase clinical trials. Dr Drew is deputy lead for the Newcastle Experimental Cancer Medicines Centre for early phase clinical trials delivery, a member of both the NCRI Ovarian and Endometrial clinical studies sub-groups and PI and national CI on a number of endometrial and ovarian cancer trials. Research interests lie in targeting DNA repair pathways as treatment for cancer.

IECC Live Sessions Information

During the duration of the conference, a number of live online sessions will be programmed. Each session will consist on 1–4 speakers lecturing on special topics, and will be moderated by a chair. During each session, the participants will have the possibility to ask questions during a Q&A session. Detailed information about the topics will be shared later.

The live sessions are free. The number of participants to the live session is limited but the recording will be made available on Sciforum shortly afterwards.

Program of IECC Live Sessions

1 February 2021

Session 1: Overview of targeting DDR dysfunction in cancer

Date: 1 February 2021

Time: 12:00pm (GMT) | 07:00am (EDT) | 8:00pm (CST Asia)

Speaker

Presentation Topic

Time (GMT)

Keynote Speaker
Prof. Kum Kum Khanna

Targeting DNA damage response pathway basic mechanisms and translational implications

12:00pm – 12:45pm

1 February 2021

Session 2: DNA damage cell cycle checkpoints

Date: 1 February 2021

Time: 12:45pm (GMT) | 07:45am (EDT) | 8:45pm (CST Asia)

Speaker

Presentation Topic

Time (GMT)

Chair and plenary speaker
Prof. Dr. Karlene A. Cimprich

The Causes and Consequences of Replication Stress

12:45pm - 13:15pm

Dr. Ruth Thompson

A novel DNA damage checkpoint in mitosis

13:15pm - 13:30pm

Dr. Gro Elise Rødland

Differential effects of combined ATR/WEE1

13:30pm - 13:45pm

Dr. Shan Yan

Distinct mechanisms of ATR-Chk1 DNA damage response pathway in response to DNA single-strand break

13:45pm - 14:00pm

1 February 2021

Session 3: DNA repair, defects in cancer and their exploitation

Date: 1 February 2021

Time: 14:30pm (GMT) | 09:30m (EDT) | 10:45pm (CST Asia)


Speaker

Presentation Topic

Time (GMT)

Chair and plenary speaker
Dr. Susan Lees-Miller

Targeting ATM-deficient cancers with PARP inhibitors

14:30pm – 15:00pm

Dr. Laura Monaghan

KDM4A inhibition sensitises Acute Myeloid Leukaemia cells to PARP inhibitors through impairing Non-Homologous End Joining pathway and enhancing PARP trapping

15:00pm – 15:15pm

Dr. David King

MYCN over-expression in Neuroblastoma potentiates PARP inhibitor induced radiosensitization

15:15pm – 15:30pm

Dr. Mats Ljungman

Specific induction of DSBs in cancer cells by targeting chromosome rearrangements with CRISPR Technology

15:15pm – 15:30pm

2 February 2021

Session 4: MMR defects, mutator phenotype

Date: 2 February 2021

Time: 12:00pm (GMT) | 07:00am (EDT) | 8:00pm (CST Asia)

Speaker

Presentation Topic

Time (GMT)

Chair and plenary speaker
Dr. Sarah-Anne Martin

Targeting DNA MMR loss as a therapeutic strategy in cancer

12:00pm – 12:30pm

Dr. Tuyen Dang

Elucidating the role of XRN2-mediated DNA repair programs

12:30pm – 12:45pm

Dr. Victoria Dunne

Synergistic activity of DNA damage response kinase inhibitors in combination with the targeted alpha therapy radium-223 dichloride for metastatic castration-resistant prostate cancer

12:45pm – 13:00pm

Dr. Carolina Velázquez

Exploiting DNA Repair Defect in Triple Negative Brest Cancer Using CDK Inhibition Strategy

13:00pm – 13:15pm

2 February 2021

Session 5: SUMO and Ubiquitination and other epigenetic and post-translational mechanisms

Date: 2 February 2021

Time: 14:00pm (GMT) | 09:00am (EDT) | 10:00pm (CST Asia)

Speaker

Presentation Topic

Time (GMT)

Chair
Dr. Ruth Thompson

N/A

Plenary speaker
Prof. Dr. Jo Morris


The role of SUMO in DNA double-strand break repair

14:00pm – 14:30pm

Dr. Yi Sheng

An Integrated Structure-based Approach for the Development of MDM2 inhibitors

14:30pm – 14:45pm

Dr. Alexandre Maréchal

SMARCAL1 Ubiquitylation Controls its Association with RPA-ssDNA and Promotes Fork Stability

14:45pm – 15:00pm

Dr. Tham Thi Nguyen

Epigenetic deregulation of nuclear transport impacts DNA repair capacity and treatment resistance in glioblastoma

15:00pm – 15:15pm

3 February 2021

Session 6: Targeting with immune checkpoint inhibitors

Date: 3 February 2021

Time: 12:00pm (GMT) | 07:00am (EDT) | 8:00pm (CST Asia)

Speaker

Presentation Topic

Time (GMT)

Chair and plenary speaker
Dr. Juanita Suzanne Lopez

Making invisible tumours visible – what next after Immune Checkpoint Inhibitors?

12:00pm - 12:30pm

Dr. Cucchi Danilo

Mechanistic investigation of response to immune checkpoint blockade upon DNA Damage

12:30pm - 12:45pm

Dr. Jing Zhang

Anti-inflammatory combinatorial therapy to enhance killing efficacy with patient-derived preclinical models

12:45pm - 13:00pm

Dr. Jian Li

Depleting upregulated DNA polymerase theta (pol θ) in esophageal squamous cell carcinoma (ESCC) inhibits tumor growth, promotes genome instability, and induces ISGs expression through cGAS activation

13:00pm - 13:15pm

3 February 2021

Session 7: Overview and use of biomarkers in clinical trials

Date: 3 February 2021

Time: 14:00pm (GMT) | 09:00am (EDT) | 10:00pm (CST Asia)

Speaker

Presentation Topic

Time (GMT)

Chair and plenary speaker
Dr. Yvette Drew

A moving target - the use of predictive biomarkers in the targeting the DNA damage response in cancer

14:00pm – 14:30pm

Dr. Françoise Dantzer

The therapeutic significance of PARP3 inhibition in highly aggressive cancers

14:30pm – 14:45pm

Dr. Jason Parsons

Targeting the cellular DNA damage response following proton beam therapy

14:45pm – 15:00pm

Prof. Dr. Michael Hausmann

Space and time in the universe of the cell nucleus after ionizing radiation attacks: a comparison of cancer and non-cancer cell response

15:00pm – 15:15pm

Online Sessions Recordings

In this section, you will find the recordings of the Live Sessions to watch, re-watch and share with your colleagues!

1 February 2021

Session 1 - Overview of targeting DDR dysfunction in cancer

Session 2 - DNA damage cell cycle checkpoints

Session 3 - DNA repair, defects in cancer and their exploitation

2 February 2021

Session 4 - MMR defects, mutator phenotype

Session 5 - SUMO and Ubiquitination and other epigenetic and post-translational mechanisms

3 February 2021

Session 6 - Targeting With Immune Checkpoint Inhibitors

Session 7 - Overview and Use of Biomarkers in Clinical Trials

List of accepted submissions (43)

Id Title Authors Presentation Video Presentation Pdf
sciforum-041979 5-aminosalicylate–4-thiazolinone hybrid derivatives: A potent modulator of DNA damage response and G2/M cell cycle arrest via ATM/ATR pathway and Cyclin-CDK complex

Wafaa Ramadan, Maha Ayad, Rifat Hamoudi, Amina Laham, Varsha Menon, Lama Lozon, Hajjaj Abdu-Allah, Abdel-Nasser El-Shorbagi, Hamadeh Tarazi, Raafat El-Awady

Submitted: 05 Dec 2020

Abstract: Show Abstract
Wafaa Ramadan, Maha Ayad, Rifat Hamoudi, Amina Laham, Varsha Menon, Lama Lozon, Hajjaj Abdu-Allah, Abdel-Nasser El-Shorbagi, Hamadeh Tarazi, Raafat El-Awady N/A Poster PDF Show Abstract
sciforum-041279 ARID1A: The Good, the Bad and the Ugly.

Paola Peinado, Alvaro Andrades, Juan Sanjuan-Hidalgo, Jeffrey Haswell, Juan Alvarez-Perez, Frank Slack, Pedro Medina Vico

Submitted: 11 Nov 2020

Abstract: Show Abstract
Paola Peinado, Alvaro Andrades, Juan Sanjuan-Hidalgo, Jeffrey Haswell, Juan Alvarez-Perez, Frank Slack, Pedro Medina Vico N/A Poster PDF Show Abstract
sciforum-041466 An Integrated Structure-based Approach for the Development of MDM2 inhibitors

Yi Sheng

Submitted: 15 Nov 2020

Abstract: Show Abstract
Yi Sheng N/A Poster PDF Show Abstract
sciforum-041448 Anti-inflammatory combinatorial therapy to enhance killing efficacy with patient-derived preclinical models

Jing Zhang, Bee Luan KHOO

Submitted: 14 Nov 2020

Abstract: Show Abstract
Jing Zhang, Bee Luan KHOO N/A Poster PDF Show Abstract
sciforum-041981 BRAT1 impairs DNA damage repair in glioblastoma cell lines Johanna Ertl, Ömer Güllülü, Stephanie Hehlgans, Franz Rödel, Donat Kögel, Benedikt Linder Video Thumbnail Poster PDF Show Abstract

Instructions for Authors

Submission Information

Submissions should be made by authors online by registering with www.sciforum.net and using the "New Submission" function once logged into the system.

  1. Scholars interested in participating in the conference can submit their abstract (about 200–300 words) online on this website until 6 December 2020.
  2. The Conference Committee will notify the acceptance of the abstract by 20 December 2020.
  3. In case of acceptance, authors will be asked to submit their manuscript (short proceedings paper, 3-6 pages), along with a presentation, and optionally a video presentation of his/her paper (only PDF), until the submission deadline of 20 January 2021.
  4. The manuscripts and presentations will be available on IECC2021.sciforum.net for discussion and rating during the time of the conference, from 1–14 February 2021.
  5. All accepted proceedings papers will be published as one dedicated volume in MDPI Proceedings series journals (ISSN: 2504-3900). Publication of proceedings paper is free of charge.
  6. The open access journal Cancers (IF 6.126) will publish a conference Special IssueIECC2021: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response”. All participants are cordially invited to contribute with a full manuscript to this Special Issue.
Proceedings Paper

Manuscripts for the proceedings issue must have the following organization:

First page:

  • Title
  • Full author names
  • Affiliations (including full postal address) and authors' e-mail addresses
  • Abstract
  • Keywords
  • Introduction
  • Methods
  • Results and Discussion
  • Conclusions
  • (Acknowledgements)
  • References

Manuscripts should be prepared in MS Word or any other word processor and should be converted to PDF format before submission. The publication format will be PDF. The manuscript should count at least 3 pages (incl. figures, tables and references) and should not exceed 6 pages.

Presentation Slides

Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the manuscript. Slides, if available, will be displayed directly on the website using the IECC2021.sciforum.net proprietary slide viewer. Slides can be prepared in exactly the same way as for any traditional conference where research results are presented. Slides should be converted to PDF format before submission so that our process can easily and automatically convert them for online display.

Video Presentations

Authors are also encouraged to submit video presentations. If you are interested in submitting a video presentation, please contact the conference organizer at [email protected] to find out more about the procedure. The video should be no longer than 10 minutes and be prepared as any of the following formats: .MOV; .MPEG4; .MP4; .AVI; .WMV; .MPEGPS; .FLV.

Presentation of Posters

Authors that wish to present a poster only, i.e., without proceedings paper, can do so in the poster session (session 8). Posters will be available on this conference website during and after the event. Like papers presented on the conference, participants will be able to ask questions and make comments about the posters. Posters can be presented without an accompanying proceedings paper and will be available online on this website during and after the e-conference. However, they will not be added to the proceedings of the conference.

Submission of Manuscripts

Submission: Manuscripts should be submitted online at www.sciforum.net/login by registering and logging in.

Accepted File Formats

  • MS Word: Manuscripts prepared in MS Word must be converted into a single file before submission. When preparing manuscripts in MS Word, the 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response Microsoft Word template file (see download below) must be used. Please do not insert any graphics (schemes, figures, etc.) into a movable frame, as they can superimpose the text and make the layout very difficult to work with.
  • LaTeX: Manuscripts prepared in LaTeX must be collated into one ZIP folder (including all source files and images, so that the Conference Secretariat can recompile the submitted PDF). When preparing manuscripts in LaTeX, please use the 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response LaTeX template files.

The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response

LaTeX template

Manuscript Preparation

Paper Format: A4 paper format; the printing area is 17.5 cm × 26.2 cm. The margins should be 1.75 cm on each side of the paper (top, bottom, left, and right sides).

  • Formatting/Style: Papers should be prepared following the style of Proceedings. The full titles and the cited papers must be given. Reference numbers should be placed in square brackets [ ], and placed before the punctuation; for example, [1,2], [3] or [1–3], and all the references should be listed separately, and as the last section at the end of the manuscript.
  • Author List and Affiliation Format: Authors' full first and last names must be given. Abbreviated middle names can be added. For papers written by various contributors, a corresponding author must be designated. The PubMed/MEDLINE format is used for affiliations: complete street address information including city, zip code, state/province, country, and email address should be added. All authors who contributed significantly to the manuscript (including writing a section) should be listed on the first page of the manuscript, below the title of the article. Other parties, who provided only minor contributions, should be listed under Acknowledgments only. A minor contribution might be a discussion with the author, reading through the draft of the manuscript, or performing English corrections.
  • Figures, Schemes and Tables: Authors are encouraged to prepare figures and schemes in color. Full color graphics will be published free of charge. Figures and schemes must be numbered (Figure 1, Scheme I, Figure 2, Scheme II, etc.) and an explanatory title must be added. Tables should be inserted into the main text, and numbers and titles for all tables supplied. All table columns should have an explanatory heading. Please supply legends for all figures, schemes and tables. The legends should be prepared as a separate paragraph of the main text and placed in the main text before a table, a figure or a scheme.

For further enquiries, please contact us at [email protected].

Potential Conflicts of Interest

It is the authors' responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state here "The authors declare no conflict of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Financial support for the study must be fully disclosed under the "Acknowledgments" section.

Copyright

MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their scholarly works. Hence, by submitting a communication paper to this conference, you retain the copyright of your paper, but you grant MDPI the non-exclusive right to publish this paper online on the Sciforum.net platform. This means that you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).

Event Awards

To acknowledge the support of the conference esteemed authors, and to recognize their outstanding scientific accomplishments, we are pleased to launch the Best Paper Awards and Best Poster Awards.

The Awards
Best Paper Award (500 CHF)
The Best Paper Award is given to the paper judged to make the most significant contribution to the conference.
Best Poster Awards (500 CHF)
The Best Poster Awards have been established to recognize the scientific merit exhibited in poster presentation and preparation.
Terms and Conditions:

Best Paper Award

As a sponsor, Cancers would like to award the best paper as elected by all the conference committee. The award will consist of 500 Swiss Francs. We look forward to reviewing your contributions.

Criteria for Evaluation of Best Paper Award:

Criteria

  • Full paper must be submitted to IECC 2021 conference;
  • Originality/novelty of the paper;
  • Significance of content;
  • Scientific soundness;
  • Interest to the readers;
  • English language and style.

Evaluation

  • Each Evaluation Committee member will give an assessment for each applicant in terms of the criteria outlined above;
  • Total score for each presentation will be ranked, from highest to lowest;
  • If two or more authors get the same score, a further evaluation will be carried out;
  • All decisions made by the Evaluation Committee are final.

Best Poster Awards

As a sponsor, Cancers would like to grants an award (500 Swiss Francs) for the best poster presented at the conference. This prize is awarded by a jury to the best designed poster presented at the conference.

Posters should have the following information.

  • Title (with authors and affiliations)
  • Introduction/objectives/aims
  • Methods
  • Results
  • Conclusion
  • References
  • Acknowledgements
  • Contact information

Criteria of judgement on the presentation will be the ability to summarize the content of the work and to motivate people’s interest who look at the poster. Criteria of judgement on the poster will be clarity of poster and appearance quality.

Winner:

Responsive signatures established by pharmaco-transcriptomic correlation analysis identifies subsets for PARP-targeted therapy and reveals potential synergistic interactors(doi:10.3390/IECC2021-09207)

Haitang Yang * , Beibei Sun, Sean R R R. R. Hall, Ke Xu, Liang Zhao, Ralph A. Schmid, Ren-Wang Peng, Feng Yao

Winners:

Increased replication stress sensitises high risk neuroblastoma cells to ATR and PARP inhibition(doi:10.3390/IECC2021-09205)

Harriet Southgate *, Lindi Chen, Deborah A Tweddle, Nicola J Curtin*

Targeting OGG1 arrests cancer cell proliferation by inducing replication stress (doi: 10.3390/IECC2021-09213)

Bishoy M. F. Hanna, Torkild Visnes, Carlos Benitez-Buelga, Armando Cazares-Körner, Kumar Sanjiv, Oliver Mortusewicz, Geoffrey Masuyer, Olov Wallner, Maurice Michel, Olga Loseva, Ann-Sofie Jemth, Christina Kalderen, Pal Stenmark, Ulrika Warpman Berglund, Thomas Helleday *

Conference Organizers

Cancers

https://www.mdpi.com/journal/cancers

DETAILS

Cancers (ISSN 2072-6694; CODEN: CANCCT) is a peer-reviewed Open Access journal of oncology published monthly online by MDPI.

Introduction

Cancers (ISSN 2072-6694; CODEN: CANCCT) is a peer-reviewed Open Access journal of oncology published monthly online by MDPI.

Sponsors and Partners

Cancers (ISSN 2072-6694; CODEN: CANCCT) is a peer-reviewed Open Access journal of oncology published monthly online by MDPI.

Organizers

Top